Workshops on ATMP development very well received

Published 13 July 2016

EATRIS was honored to Co-organize its second international 2-day workshop with the Ri.MED foundation on ATMP development last month in Palermo, Sicily following the success of the first such course held at the Istituto Superiore di Sanità (ISS) in Rome in September. The EATRIS & ISS Introductory ATMP Development Regulatory course, under the scientific direction of Maria Cristina Galli (ISS), provided participants with presentations from key opinion leaders in the ATMP field providing enthusiastic participants with a sound understanding of pre-clinical and clinical requirements for ATMP development.

In addition, this meeting successfully focused on how ATMP regulatory requirements can be achieved in a timely and cost effective manner. In a similar fashion, our co-organized Palermo workshop consisted of a rich and varied content with 8 keynote speakers from different stages of the ATMP development pipeline, including a panel discussion and informal networking opportunities. This informative workshop was host to multiple stakeholders in the ATMP development pathway including SMEs, pharma, academics and a large number of students in the field.

An electronic audience response system actively involved the audience and contributed to a very stimulating and vibrant atmosphere. Participants from Academia and Biotech viewed this workshop as a successful educational tool for the challenging ATMP development pipeline (94% of respondents stating that the course will make a difference in the way they do their job). This excellent collaboration between EATRIS as the contractor to design and deliver the training content, and the very efficient and collaborative Ri.MED staff who organised the venue and logistics, resulted in a productive and stimulating workshop. This workshop, in a similar fashion to our equally well-received ATMP workshop at Istituto Superiore di Sanità, in Rome in September, contribute greatly to improving translational research for the development of Advanced Therapy Medicinal Products, which have real positive impact on public health.

More information and program